ACT-001
/ WuXi AppTec
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 21, 2024
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
(clinicaltrials.gov)
- P=N/A | N=18 | Not yet recruiting | Sponsor: RenJi Hospital
New trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1